The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
43
Unnamed facility
Fukuoka, Fukuoka, Japan
Unnamed facility
Gifu, Gifu, Japan
Unnamed facility
Hiroshima, Hiroshima, Japan
Unnamed facility
Asahikawa, Hokkaido, Japan
Change from baseline in serum phosphate levels at the end of the treatment period
Time frame: Baseline to Week 8
Number of participants achieving the target PSPL (Pre-dialysis serum phosphate level) and time to achievement
Time frame: Week 8
Serum calcium level corrected by serum albumin level at the end of the treatment period
Time frame: Week 8
Serum calcium x phosphate product at the end of the treatment period
Time frame: Week 8
Serum intact-PTH (Parathyroid) levels at the end of the treatment period
Time frame: Week 8
Safety variables will be summarized using descriptive statistics based on adverse events collection
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Kamakura, Kanagawa, Japan
Unnamed facility
Yokosuka, Kanagawa, Japan
Unnamed facility
Ōsaki, Miyagi, Japan
Unnamed facility
Sendai, Miyagi, Japan
Unnamed facility
Okayama, Okayama-ken, Japan
Unnamed facility
Tokushima, Tokushima, Japan
...and 1 more locations